23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › HERON THERAPEUTICS INC. › 2023-2024

HERON THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and HERON THERAPEUTICS INC.’s Form 8-K, filed June 18, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 11Ballot items
  • 160Asset managers, any item
  • 1,473Fund votes
  • June 13, 2024Meeting date

Results at a glance

Meeting of June 13, 2024: 11 items on HERON THERAPEUTICS INC.’s Form 8-K, filed June 18, 2024: 11 passed (calculated).

Dissent

Significant dissent: 1 equity or compensation plan (28.0% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Rubric Capital (13D, 15.9%, as of October 17, 2025) · Clearline Capital (13F, 5.8%, as of September 30, 2026) · Tang Capital (13F, 4.7%, as of September 30, 2026)

Explore HERON THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by HERON THERAPEUTICS INC.

These tallies are HERON THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

HERON THERAPEUTICS INC. — official shareholder meeting results, meeting held June 13, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Mr. Collard 87,052,188622,0981,794,705 --29,159,734 99.3%Passed (calculated)—
Elect Director: Dr. Dissanaike 86,622,579875,3371,971,075 --29,159,734 99%Passed (calculated)—
Elect Director: Mr. Johnson 86,610,323864,3461,994,322 --29,159,734 99.0%Passed (calculated)—
Elect Director: Mr. Morgan 86,819,401667,5611,982,029 --29,159,734 99.2%Passed (calculated)—
Elect Director: Ms. Rodriguez 86,593,635879,7931,995,563 --29,159,734 99%Passed (calculated)—
Elect Director: Mr. Waage 86,762,924711,9261,994,141 --29,159,734 99.2%Passed (calculated)—
2. Ratification of the appointment of Withum Smith+Brown, PC as the Company's independent registered public accounting firm for the year ending December 31, 2024 114,364,367358,5273,905,831 --0 99.7%Passed (calculated)—
3. Nonbinding advisory vote to approve compensation paid to the Company's Named Executive Officers during the year ended December 31, 2023 72,711,98814,427,2052,329,798 --29,159,734 83%Passed (calculated)—
4. Amendment to the Company's Certificate of Incorporation, as amended, to increase the aggregate number of authorized shares of the Company's common stock by 175,000,000 from 225,000,000 to 400,000,000 104,392,52711,372,0282,864,170 --0 90%Passed (calculated)—
5. Amendment to the Company's 2007 Amended and Restated Equity Incentive Plan to increase the number of shares of the Company's common stock authorized for issuance thereunder by 7,500,000 from 39,190,000 to 46,690,000 62,949,44824,467,4112,052,132 --29,159,734 72%Passed (calculated)—
6. Amendment to the Company's 1997 Employee Stock Purchase Plan, as amended, to increase the number of shares of the Company's common stock authorized for issuance thereunder by 1,200,000 from 2,225,000 to 3,425,000 82,707,2745,000,6321,761,085 --29,159,734 94%Passed (calculated)—

Source: HERON THERAPEUTICS INC., Form 8-K, filed with the SEC on June 18, 2024 — read the filing on EDGAR.

How asset managers voted at the HERON THERAPEUTICS INC. 2023-2024 meeting

160 asset managers disclosed a vote on at least one HERON THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Mr. Morgan

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99.2% Majority: yes · of votes cast

FOR 99.2%
FOR: 86,819,401AGAINST: 667,561
Details: description as filed, official tally, votes by 42 asset managers

Description as filed by funds: To elect six director nominees to serve until the 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Adam Morgan

HERON THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mr. Morgan”): 86,819,401 for, 667,561 against, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 12,610,374 for, 34,692 abstained.

FOR
FOR: 12,610,374ABSTAIN: 34,692
Largest asset managers voting on “To elect six director nominees to serve until the 2025 Annual Meeting of Stockholders and until their successo” at HERON THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,357,3340 00For
BlackRock2,600,0530 00For
FRANKLIN STRATEGIC SERIES1,632,6920 00For
State Street582,7750 00For
Charles Schwab502,9400 00For
Equitable274,6080 00For
SEI240,9110 00For
HIGHLAND GLOBAL ALLOCATION FUND232,8000 00For
Jacob Funds Inc.224,1080 00For
QUANTITATIVE MASTER SERIES LLC185,3130 00For
Lincoln Financial134,7000 00For
TIAA116,6280 00For
Fidelity93,9890 00For
Federated Hermes47,9930 00For
Northern Trust46,8030 00For
Zacks Trust41,3480 00For
AuguStar00 34,6920Abstain
Pacific Life33,1050 00For
Voya32,3330 00For
Bridge Builder Trust24,5180 00For
Legg Mason21,9260 00For
John Hancock19,7290 00For
Brighthouse19,3190 00For
AQR19,1910 00For
Victory Capital18,7620 00For

Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).

Elect Director: Mr. Waage

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99.2% Majority: yes · of votes cast

FOR 99.2%
FOR: 86,762,924AGAINST: 711,926
Details: description as filed, official tally, votes by 42 asset managers

Description as filed by funds: To elect six director nominees to serve until the 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Christian Waage

HERON THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mr. Waage”): 86,762,924 for, 711,926 against, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 12,603,246 for, 7,128 against, 34,692 abstained.

FOR
FOR: 12,603,246AGAINST: 7,128ABSTAIN: 34,692
Largest asset managers voting on “To elect six director nominees to serve until the 2025 Annual Meeting of Stockholders and until their successo” at HERON THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,357,3340 00For
BlackRock2,600,0530 00For
FRANKLIN STRATEGIC SERIES1,632,6920 00For
State Street582,7750 00For
Charles Schwab502,9400 00For
Equitable274,6080 00For
SEI240,9110 00For
HIGHLAND GLOBAL ALLOCATION FUND232,8000 00For
Jacob Funds Inc.224,1080 00For
QUANTITATIVE MASTER SERIES LLC185,3130 00For
Lincoln Financial134,7000 00For
TIAA116,6280 00For
Fidelity93,9890 00For
Federated Hermes47,9930 00For
Northern Trust46,8030 00For
Zacks Trust41,3480 00For
AuguStar00 34,6920Abstain
Pacific Life33,1050 00For
Voya32,3330 00For
Bridge Builder Trust24,5180 00For
Legg Mason21,9260 00For
John Hancock19,7290 00For
Brighthouse19,3190 00For
AQR19,1910 00For
Victory Capital18,7620 00For

Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).

Elect Director: Mr. Collard

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%
FOR: 87,052,188AGAINST: 622,098
Details: description as filed, official tally, votes by 42 asset managers

Description as filed by funds: To elect six director nominees to serve until the 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Craig Collard

HERON THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mr. Collard”): 87,052,188 for, 622,098 against, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 12,610,374 for, 34,692 abstained.

FOR
FOR: 12,610,374ABSTAIN: 34,692
Largest asset managers voting on “To elect six director nominees to serve until the 2025 Annual Meeting of Stockholders and until their successo” at HERON THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,357,3340 00For
BlackRock2,600,0530 00For
FRANKLIN STRATEGIC SERIES1,632,6920 00For
State Street582,7750 00For
Charles Schwab502,9400 00For
Equitable274,6080 00For
SEI240,9110 00For
HIGHLAND GLOBAL ALLOCATION FUND232,8000 00For
Jacob Funds Inc.224,1080 00For
QUANTITATIVE MASTER SERIES LLC185,3130 00For
Lincoln Financial134,7000 00For
TIAA116,6280 00For
Fidelity93,9890 00For
Federated Hermes47,9930 00For
Northern Trust46,8030 00For
Zacks Trust41,3480 00For
AuguStar00 34,6920Abstain
Pacific Life33,1050 00For
Voya32,3330 00For
Bridge Builder Trust24,5180 00For
Legg Mason21,9260 00For
John Hancock19,7290 00For
Brighthouse19,3190 00For
AQR19,1910 00For
Victory Capital18,7620 00For

Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).

Elect Director: Mr. Johnson

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99.0% Majority: yes · of votes cast

FOR 99.0%
FOR: 86,610,323AGAINST: 864,346
Details: description as filed, official tally, votes by 42 asset managers

Description as filed by funds: To elect six director nominees to serve until the 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Craig Johnson

HERON THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mr. Johnson”): 86,610,323 for, 864,346 against, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.0% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 12,561,961 for, 48,413 against, 34,692 abstained.

FOR
FOR: 12,561,961AGAINST: 48,413ABSTAIN: 34,692
Largest asset managers voting on “To elect six director nominees to serve until the 2025 Annual Meeting of Stockholders and until their successo” at HERON THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,357,3340 00For
BlackRock2,600,0530 00For
FRANKLIN STRATEGIC SERIES1,632,6920 00For
State Street582,7750 00For
Charles Schwab502,9400 00For
Equitable274,6080 00For
SEI240,9110 00For
HIGHLAND GLOBAL ALLOCATION FUND232,8000 00For
Jacob Funds Inc.224,1080 00For
QUANTITATIVE MASTER SERIES LLC185,3130 00For
Lincoln Financial134,7000 00For
TIAA116,6280 00For
Fidelity93,9890 00For
Federated Hermes047,993 00Against
Northern Trust46,8030 00For
Zacks Trust41,3480 00For
AuguStar00 34,6920Abstain
Pacific Life33,1050 00For
Voya32,3330 00For
Bridge Builder Trust24,5180 00For
Legg Mason21,9260 00For
John Hancock19,7290 00For
Brighthouse19,3190 00For
AQR19,1910 00For
Victory Capital18,7620 00For

Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).

Elect Director: Dr. Dissanaike

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 86,622,579AGAINST: 875,337
Details: description as filed, official tally, votes by 42 asset managers

Description as filed by funds: To elect six director nominees to serve until the 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Sharmila Dissanaike, M.D., FACS, FCCM

HERON THERAPEUTICS INC.’s own tally for this item (“Elect Director: Dr. Dissanaike”): 86,622,579 for, 875,337 against, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 12,561,961 for, 48,413 against, 34,692 abstained.

FOR
FOR: 12,561,961AGAINST: 48,413ABSTAIN: 34,692
Largest asset managers voting on “To elect six director nominees to serve until the 2025 Annual Meeting of Stockholders and until their successo” at HERON THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,357,3340 00For
BlackRock2,600,0530 00For
FRANKLIN STRATEGIC SERIES1,632,6920 00For
State Street582,7750 00For
Charles Schwab502,9400 00For
Equitable274,6080 00For
SEI240,9110 00For
HIGHLAND GLOBAL ALLOCATION FUND232,8000 00For
Jacob Funds Inc.224,1080 00For
QUANTITATIVE MASTER SERIES LLC185,3130 00For
Lincoln Financial134,7000 00For
TIAA116,6280 00For
Fidelity93,9890 00For
Federated Hermes047,993 00Against
Northern Trust46,8030 00For
Zacks Trust41,3480 00For
AuguStar00 34,6920Abstain
Pacific Life33,1050 00For
Voya32,3330 00For
Bridge Builder Trust24,5180 00For
Legg Mason21,9260 00For
John Hancock19,7290 00For
Brighthouse19,3190 00For
AQR19,1910 00For
Victory Capital18,7620 00For

Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).

Elect Director: Ms. Rodriguez

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 86,593,635AGAINST: 879,793
Details: description as filed, official tally, votes by 42 asset managers

Description as filed by funds: To elect six director nominees to serve until the 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Susan Rodriguez

HERON THERAPEUTICS INC.’s own tally for this item (“Elect Director: Ms. Rodriguez”): 86,593,635 for, 879,793 against, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 12,561,961 for, 48,413 against, 34,692 abstained.

FOR
FOR: 12,561,961AGAINST: 48,413ABSTAIN: 34,692
Largest asset managers voting on “To elect six director nominees to serve until the 2025 Annual Meeting of Stockholders and until their successo” at HERON THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,357,3340 00For
BlackRock2,600,0530 00For
FRANKLIN STRATEGIC SERIES1,632,6920 00For
State Street582,7750 00For
Charles Schwab502,9400 00For
Equitable274,6080 00For
SEI240,9110 00For
HIGHLAND GLOBAL ALLOCATION FUND232,8000 00For
Jacob Funds Inc.224,1080 00For
QUANTITATIVE MASTER SERIES LLC185,3130 00For
Lincoln Financial134,7000 00For
TIAA116,6280 00For
Fidelity93,9890 00For
Federated Hermes047,993 00Against
Northern Trust46,8030 00For
Zacks Trust41,3480 00For
AuguStar00 34,6920Abstain
Pacific Life33,1050 00For
Voya32,3330 00For
Bridge Builder Trust24,5180 00For
Legg Mason21,9260 00For
John Hancock19,7290 00For
Brighthouse19,3190 00For
AQR19,1910 00For
Victory Capital18,7620 00For

Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).

Amendment to the Company's Certificate of Incorporation, as amended, to increase the aggregate number of authorized…

Calculated outcomeCAPITAL STRUCTUREPassed (calculated)

90% Majority: yes · of votes cast

FOR 90%
FOR: 104,392,527AGAINST: 11,372,028
Details: description as filed, official tally, votes by 42 asset managers

Description as filed by funds: TO AMEND THE COMPANY'S CERTIFICATE OF INCORPORATION TO INCREASE THE AGGREGATE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK BY 175,000,000 FROM 225,000,000 TO 400,000,000.

HERON THERAPEUTICS INC.’s own tally for this item (“4. Amendment to the Company's Certificate of Incorporation, as amended, to increase the aggregate number of authorized shares of the Company's common stock by 175,000,000 from 225,000,000 to 400,000,000”): 104,392,527 for, 11,372,028 against, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 12,548,714 for, 96,352 against.

FOR
FOR: 12,548,714AGAINST: 96,352
Largest asset managers voting on “TO AMEND THE COMPANY'S CERTIFICATE OF INCORPORATION TO INCREASE THE AGGREGATE NUMBER OF AUTHORIZED SHARES OF C” at HERON THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,357,3340 00For
BlackRock2,600,0530 00For
FRANKLIN STRATEGIC SERIES1,632,6920 00For
State Street582,7750 00For
Charles Schwab502,9400 00For
Equitable274,6080 00For
SEI240,9110 00For
HIGHLAND GLOBAL ALLOCATION FUND232,8000 00For
Jacob Funds Inc.162,44861,660 00Mixed
QUANTITATIVE MASTER SERIES LLC185,3130 00For
Lincoln Financial134,7000 00For
TIAA116,6280 00For
Fidelity93,9890 00For
Federated Hermes47,9930 00For
Northern Trust46,8030 00For
Zacks Trust41,3480 00For
AuguStar034,692 00Against
Pacific Life33,1050 00For
Voya32,3330 00For
Bridge Builder Trust24,5180 00For
Legg Mason21,9260 00For
John Hancock19,7290 00For
Brighthouse19,3190 00For
AQR19,1910 00For
Victory Capital18,7620 00For

Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).

Amendment to the Company's 1997 Employee Stock Purchase Plan, as amended, to increase the number of shares of the…

Calculated outcomeCOMPENSATIONPassed (calculated)

Combines 2 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 82,707,274AGAINST: 5,000,632
Details: description as filed, official tally, votes by 43 asset managers

Description as filed by funds: TO AMEND THE ESPP TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE THEREUNDER BY 1,200,000 FROM 2,225,000 TO 3,425,000.

HERON THERAPEUTICS INC.’s own tally for this item (“6. Amendment to the Company's 1997 Employee Stock Purchase Plan, as amended, to increase the number of shares of the Company's common stock authorized for issuance thereunder by 1,200,000 from 2,225,000 to 3,425,000”): 82,707,274 for, 5,000,632 against, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 43 asset managers below reported 12,588,876 for, 96,352 against.

FOR
FOR: 12,588,876AGAINST: 96,352
Largest asset managers voting on “TO AMEND THE ESPP TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE THEREUNDER BY 1,200” at HERON THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,357,3340 00For
BlackRock2,600,0530 00For
FRANKLIN STRATEGIC SERIES1,632,6920 00For
State Street582,7750 00For
Charles Schwab502,9400 00For
Equitable274,6080 00For
SEI240,9110 00For
HIGHLAND GLOBAL ALLOCATION FUND232,8000 00For
Jacob Funds Inc.162,44861,660 00Mixed
QUANTITATIVE MASTER SERIES LLC185,3130 00For
Lincoln Financial134,7000 00For
TIAA116,6280 00For
Fidelity93,9890 00For
Federated Hermes47,9930 00For
Northern Trust46,8030 00For
Zacks Trust41,3480 00For
GRIMES & COMPANY, INC.40,1620 00For
AuguStar034,692 00Against
Pacific Life33,1050 00For
Voya32,3330 00For
Bridge Builder Trust24,5180 00For
Legg Mason21,9260 00For
John Hancock19,7290 00For
Brighthouse19,3190 00For
AQR19,1910 00For

Showing the 25 largest of 43 asset managers. All 43 are in the interactive database (link above).

Amendment to the Company's 2007 Amended and Restated Equity Incentive Plan to increase the number of shares of the…

Calculated outcomeCOMPENSATIONPassed (calculated)

72% Majority: yes · of votes cast

FOR 72%AGAINST
FOR: 62,949,448AGAINST: 24,467,411

Prior year: 79.0% for (June 6, 2023 meeting) ▼ 7.0 pts

Details: description as filed, official tally, votes by 42 asset managers

Description as filed by funds: TO AMEND THE 2007 PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE THEREUNDER BY 7,500,000 FROM 39,190,000 TO 46,690,000.

HERON THERAPEUTICS INC.’s own tally for this item (“5. Amendment to the Company's 2007 Amended and Restated Equity Incentive Plan to increase the number of shares of the Company's common stock authorized for issuance thereunder by 7,500,000 from 39,190,000 to 46,690,000”): 62,949,448 for, 24,467,411 against, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 72% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 10,944,463 for, 1,665,911 against, 34,692 abstained.

FOR
FOR: 10,944,463AGAINST: 1,665,911ABSTAIN: 34,692
Largest asset managers voting on “TO AMEND THE 2007 PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE THEREUNDER BY ” at HERON THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,357,3340 00For
BlackRock2,600,0530 00For
FRANKLIN STRATEGIC SERIES1,632,6920 00For
State Street0582,775 00Against
Charles Schwab502,9400 00For
Equitable109,578165,030 00Mixed
SEI240,9110 00For
HIGHLAND GLOBAL ALLOCATION FUND0232,800 00Against
Jacob Funds Inc.162,44861,660 00Mixed
QUANTITATIVE MASTER SERIES LLC185,3130 00For
Lincoln Financial0134,700 00Against
TIAA0116,628 00Against
Fidelity093,989 00Against
Federated Hermes47,9930 00For
Northern Trust046,803 00Against
Zacks Trust41,3480 00For
AuguStar00 34,6920Abstain
Pacific Life33,1050 00For
Voya032,333 00Against
Bridge Builder Trust24,5180 00For
Legg Mason021,926 00Against
John Hancock019,729 00Against
Brighthouse019,319 00Against
AQR019,191 00Against
Victory Capital018,762 00Against

Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).

Nonbinding advisory vote to approve compensation paid to the Company's Named Executive Officers during the year ended…

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 5 wordings of this item as funds reported it.

83% Majority: yes · of votes cast

FOR 83%AGAINST
FOR: 72,711,988AGAINST: 14,427,205

Prior year: 97.6% for (June 6, 2023 meeting) ▼ 14.1 pts

Details: description as filed, official tally, votes by 159 asset managers

Description as filed by funds: TO APPROVE, ON A NONBINDING ADVISORY BASIS, COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS DURING THE FISCAL YEAR ENDED DECEMBER 31, 2023.

HERON THERAPEUTICS INC.’s own tally for this item (“3. Nonbinding advisory vote to approve compensation paid to the Company's Named Executive Officers during the year ended December 31, 2023”): 72,711,988 for, 14,427,205 against, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 83% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 42 asset managers voting on “TO APPROVE, ON A NONBINDING ADVISORY BASIS, COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS DURING THE FISCA” at HERON THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,357,3340 00For
BlackRock2,600,0530 00For
FRANKLIN STRATEGIC SERIES1,632,6920 00For
State Street582,7750 00For
Charles Schwab0502,940 00Against
Equitable274,6080 00For
SEI0240,911 00Against
HIGHLAND GLOBAL ALLOCATION FUND0232,800 00Against
Jacob Funds Inc.224,1080 00For
QUANTITATIVE MASTER SERIES LLC185,3130 00For
Lincoln Financial134,7000 00For
TIAA116,6280 00For
Fidelity93,9890 00For
Federated Hermes047,993 00Against
Northern Trust46,8030 00For
Zacks Trust41,3480 00For
AuguStar00 34,6920Abstain
Pacific Life33,1050 00For
Voya32,3330 00For
Bridge Builder Trust24,5180 00For
Legg Mason21,9260 00For
John Hancock19,7290 00For
Brighthouse19,3190 00For
AQR19,1910 00For
Victory Capital18,7620 00For

Fund voting reports, all 42 managers: 11,576,587 for, 1,033,787 against, 34,692 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 132 asset managers voting on “TO APPROVE, ON A NONBINDING ADVISORY BASIS, COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS DURING THE FISCA” at HERON THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Rubric Capital Management LP26,713,5030 00For
ORBIMED ADVISORS LLC08,268,036 00Against
Velan Capital Investment Management LP6,986,7440 00For
FRANKLIN ADVISERS INC4,902,7030 00For
BlackRock2,634,4120 00For
PALISADE CAPITAL MANAGEMENT, LP2,292,6940 00For
JW Asset Management, LLC00 00--
Orchard Capital Management, LLC00 02,018,126Withhold
Clearline Capital LP1,747,5330 00For
State Street1,734,9980 00For
Monaco Asset Management SAM00 1,683,1640Abstain
NEW YORK STATE COMMON RETIREMENT FUND01,094,219 00Against
ADAGE CAPITAL PARTNERS GP, L.L.C.936,4180 00For
Charles Schwab0502,940 00Against
Northern Trust459,734126 00For
DE Shaw420,9540 00For
Renaissance410,3460 00For
MELLON INVESTMENTS Corp388,9830 00For
Wellington0374,702 00Against
Goldman Sachs254,6230 00For
SEI0241,411 00Against
Citadel197,3940 00For
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM170,4090 00For
AllianceBernstein165,0300 00For
STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM0163,823 00Against

Institutional-manager reports, all 132 managers: 52,007,694 for, 11,034,303 against, 2,018,126 withheld, 1,683,164 abstained, 2,292,418 unknown. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the appointment of Withum Smith+Brown, PC as the Company's independent registered public accounting…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

99.7% Majority: yes · of votes cast

FOR 99.7%
FOR: 114,364,367AGAINST: 358,527

Prior year: 99.6% for (June 6, 2023 meeting) ▲ 0.1 pts

Details: description as filed, official tally, votes by 42 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF WITHUM AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2024.

HERON THERAPEUTICS INC.’s own tally for this item (“2. Ratification of the appointment of Withum Smith+Brown, PC as the Company's independent registered public accounting firm for the year ending December 31, 2024”): 114,364,367 for, 358,527 against, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 12,610,374 for, 34,692 abstained.

FOR
FOR: 12,610,374ABSTAIN: 34,692
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF WITHUM AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR E” at HERON THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,357,3340 00For
BlackRock2,600,0530 00For
FRANKLIN STRATEGIC SERIES1,632,6920 00For
State Street582,7750 00For
Charles Schwab502,9400 00For
Equitable274,6080 00For
SEI240,9110 00For
HIGHLAND GLOBAL ALLOCATION FUND232,8000 00For
Jacob Funds Inc.224,1080 00For
QUANTITATIVE MASTER SERIES LLC185,3130 00For
Lincoln Financial134,7000 00For
TIAA116,6280 00For
Fidelity93,9890 00For
Federated Hermes47,9930 00For
Northern Trust46,8030 00For
Zacks Trust41,3480 00For
AuguStar00 34,6920Abstain
Pacific Life33,1050 00For
Voya32,3330 00For
Bridge Builder Trust24,5180 00For
Legg Mason21,9260 00For
John Hancock19,7290 00For
Brighthouse19,3190 00For
AQR19,1910 00For
Victory Capital18,7620 00For

Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).

Largest HERON THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 150,653,158 shares outstanding at the time of that meeting.

Fund voting reports: top HERON THERAPEUTICS INC. shareholders by shares voted on “TO APPROVE, ON A NONBINDING ADVISORY BASIS, COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS…”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 3.56%
2BlackRock 1.73%
3FRANKLIN STRATEGIC SERIES 1.08%
4State Street 0.39%
5Charles Schwab 0.33%
6Equitable 0.18%
7SEI 0.16%
8HIGHLAND GLOBAL ALLOCATION FUND 0.15%
9Jacob Funds Inc. 0.15%
10QUANTITATIVE MASTER SERIES LLC 0.12%
Institutional-manager reports: top HERON THERAPEUTICS INC. shareholders by shares voted on “TO APPROVE, ON A NONBINDING ADVISORY BASIS, COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS…”, 2023-2024
#Asset manager % of shares outstanding
1Rubric Capital Management LP 17.73%
2ORBIMED ADVISORS LLC 5.49%
3Velan Capital Investment Management LP 4.64%
4FRANKLIN ADVISERS INC 3.25%
5BlackRock 1.75%
6PALISADE CAPITAL MANAGEMENT, LP 1.52%
7JW Asset Management, LLC 1.52%
8Orchard Capital Management, LLC 1.34%
9Clearline Capital LP 1.16%
10State Street 1.15%

Reported HERON THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

HERON THERAPEUTICS INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Rubric Capital Management LP26,713,503 17.73%Proxy statement (DEF 14A), proxy filed April 29, 2024
BlackRock9,987,460 6.63%Form 13F, quarter ended March 31, 2024
Vanguard Group8,459,784 5.62%Form 13F, quarter ended March 31, 2024
Adam Morgan7,080,026 4.70%Proxy statement (DEF 14A), proxy filed April 29, 2024
Franklin Templeton6,374,584 4.23%Form 13F, quarter ended March 31, 2024
Geode Capital2,796,119 1.86%Form 13F, quarter ended March 31, 2024
D.E. Shaw2,695,046 1.79%Form 13F, quarter ended March 31, 2024
State Street2,440,870 1.62%Form 13F, quarter ended March 31, 2024
Renaissance Technologies2,406,486 1.60%Form 13F, quarter ended March 31, 2024
Goldman Sachs1,324,802 0.88%Form 13F, quarter ended March 31, 2024

Percentages above are of 150,653,158 shares outstanding, as reported by HERON THERAPEUTICS INC. on its Form 10-Q dated May 2, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At HERON THERAPEUTICS INC.'s shareholder meeting held June 13, 2024, in the 2023-2024 proxy season, 160 asset managers reported votes on at least one of its 11 ballot items in their SEC Form N-PX filings, covering 1,473 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON A NONBINDING ADVISORY BASIS, COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS… — FOR was 83% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: HERON THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from HERON THERAPEUTICS INC.’s 10-Q dated May 2, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

HERON THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “HERON THERAPEUTICS (HRTX) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/heron-therapeutics-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.